$KATX
KAT EXPLORATION, INC.

2024 Q2 Form 10-K Financial Statement

#000168316824004347 Filed on June 20, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $6.280K $56.33K
YoY Change 27.62%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $6.280K $11.96K $56.33K
YoY Change -85.43% 165.19% 27.61%
Operating Profit -$6.280K -$56.33K
YoY Change -85.43% 27.61%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$6.280K -$11.96K -$56.33K
YoY Change -85.43% 165.19% 27.62%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.282K -$11.96K -$56.33K
YoY Change -85.42% 165.19% 27.61%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 1.834B shares 1.834B shares 1.834B shares
Diluted Shares Outstanding 1.834B shares 1.834B shares

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.000K $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents $8.000K $0.00
Short-Term Investments
Other Short-Term Assets $5.000K $5.000K $5.000K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.00K $5.000K $5.000K
YoY Change 3746.15% 3746.15%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $13.00K $5.000K $5.000K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $13.00K $5.000K $5.000K
YoY Change 3900.0% 3746.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $13.48K $12.59K $12.59K
YoY Change 124.67% 319.77% 319.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.33K $23.52K $23.52K
YoY Change 5.61% 5.61%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $44.33K $23.52K $23.52K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $44.33K $23.52K $23.52K
YoY Change 638.88% 5.62% 5.61%
SHAREHOLDERS EQUITY
Retained Earnings -$2.750M -$2.737M
YoY Change 0.93% 2.1%
Common Stock $1.834M $1.834M
YoY Change 0.0% 2.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$31.33K -$18.52K -$18.52K
YoY Change
Total Liabilities & Shareholders Equity $13.00K $5.000K $5.000K
YoY Change 3900.0% 3746.15%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.282K -$11.96K -$56.33K
YoY Change -85.42% 165.19% 27.61%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities $0.00 -$40.10K -$60.08K
YoY Change -33516.67% 72.26%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.000K 40.10K $59.95K
YoY Change 71.3%
NET CHANGE
Cash From Operating Activities 0.000 -40.10K -$60.08K
Cash From Investing Activities $0.00
Cash From Financing Activities 8.000K 40.10K $59.95K
Net Change In Cash 8.000K 0.000000000007276 -$125.00
YoY Change -100.0% -200.81%
FREE CASH FLOW
Cash From Operating Activities $0.00 -$40.10K -$60.08K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001474558
CY2022Q4 us-gaap Prepaid Rent
PrepaidRent
usd
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
usd
CY2021 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
0 usd
CY2023 us-gaap Valuation Allowances And Reserves Period Increase Decrease
ValuationAllowancesAndReservesPeriodIncreaseDecrease
0 usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-11-30
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Public Float
EntityPublicFloat
183427 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1834271048 shares
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
5968
CY2023 dei Auditor Name
AuditorName
OLAYINKA OYEBOLA & CO.
CY2023 dei Auditor Location
AuditorLocation
Lagos Nigeria
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125 usd
CY2023Q4 us-gaap Prepaid Rent
PrepaidRent
5000 usd
CY2023Q4 us-gaap Assets
Assets
5000 usd
CY2022Q4 us-gaap Assets
Assets
125 usd
CY2023Q4 KATX Due To Related Parties Current1
DueToRelatedPartiesCurrent1
10925 usd
CY2022Q4 KATX Due To Related Parties Current1
DueToRelatedPartiesCurrent1
19266 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12593 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
23518 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22266 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1834271048 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1834271048 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1794271048 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1794271048 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1834271 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1794271 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
884054 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
864100 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2736843 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2680513 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18518 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22142 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56330 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44142 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
56330 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
44142 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-56330 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-44142 usd
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56330 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44142 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1834271048 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1834271048 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1794271048 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1794271048 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-13000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-13000 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30000 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
5000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-44142 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22142 usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
40000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
19954 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56330 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-18518 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-56330 usd
CY2023 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
3749 usd
CY2022 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-9266 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60079 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
19954 usd
CY2023 KATX Common Stock Issued For Services
CommonStockIssuedForServices
-40000 usd
CY2022 KATX Common Stock Issued For Services
CommonStockIssuedForServices
-35000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59954 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-125 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
125 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_846_eus-gaap--UseOfEstimates_zphtrL179mk9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zgGfDWEAzKUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration: underline">Concentrations of Credit Risk</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company’s cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
125 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
0 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2736843 usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-0 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
-0 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001683168-24-004347-index-headers.html Edgar Link pending
0001683168-24-004347-index.html Edgar Link pending
0001683168-24-004347.txt Edgar Link pending
0001683168-24-004347-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
katx-20231130.xsd Edgar Link pending
katx_ex3101.htm Edgar Link pending
katx_ex3102.htm Edgar Link pending
katx_ex3201.htm Edgar Link pending
katx_ex3202.htm Edgar Link pending
katx_i10k-113023.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
katx-20231130_cal.xml Edgar Link unprocessable
katx-20231130_def.xml Edgar Link unprocessable
katx-20231130_lab.xml Edgar Link unprocessable
katx-20231130_pre.xml Edgar Link unprocessable
katx_i10k-113023_htm.xml Edgar Link completed